SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:7c1fed99-8fba-4fec-848f-3c46b9d72c5b"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:7c1fed99-8fba-4fec-848f-3c46b9d72c5b" > Assessment of early...

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : : Results from the Phase II PROMIX trial

Kimbung, Siker, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Lunds Tekniska Högskola, Faculty of Engineering, LTH, Annan verksamhet, Other operations, Create Health, Create Health, Bröstcancer - prevention & intervention, Breast cancer prevention & intervention, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments, Skåne University Hospital
Markholm, Ida, (författare)
Lund University, Skåne University Hospital
Bjöhle, Judith, (författare)
Karolinska University Hospital
visa fler...
Lekberg, Tobias, (författare)
Karolinska University Hospital
Wachenfeldt, von Anna, (författare)
Karolinska University Hospital
Azavedo, Edward, (författare)
Karolinska University Hospital
Saracco, Ariel, (författare)
Karolinska University Hospital
Hellström, Mats, (författare)
Karolinska University Hospital
Veerla, Srinivas, (författare)
Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, MV, Oncology and Pathology, MV, Skåne University Hospital
Paquet, Eric, (författare)
Swiss Federal Institute of Technology
Bendahl, Pär Ola, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, MV, Oncology and Pathology, MV, Individuell Bröstcancerbehandling, Personalized Breast Cancer Treatment, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments, Skåne University Hospital
Fernö, Mårten, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, MV, Oncology and Pathology, MV, Individuell Bröstcancerbehandling, Personalized Breast Cancer Treatment, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments, Skåne University Hospital
Bergh, Jonas, (författare)
Karolinska University Hospital
Loman, Niklas, (författare)
Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, Kampradlab, Oncology and Pathology, Kamprad Lab, Onkologi och Patologi, MV, Oncology and Pathology, MV, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments, Skåne University Hospital
Hatschek, Thomas, (författare)
Karolinska University Hospital
Hedenfalk, Ingrid, (författare)
Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Medicinska fakulteten, Faculty of Medicine, Institutionen för kliniska vetenskaper, Lund, Department of Clinical Sciences, Lund, Sektion V, Division V, Onkologi och Patologi, MV, Oncology and Pathology, MV, Bröst- och ovarialcancer, Breast and Ovarian Cancer Genomics, Strategiska forskningsområden, Strategic Research Areas, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation, Starka forskningsmiljöer, Strong Research Environments, Skåne University Hospital
Bjohle, J (författare)
von Wachenfeldt, A (författare)
Hellstrom, M (författare)
Ferno, M (författare)
visa färre...
Lunds universitet Bröstcancer - prevention & intervention. (creator_code:org_t)
Lunds universitet BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation. (creator_code:org_t)
visa fler...
Lunds universitet Create Health. (creator_code:org_t)
Lunds universitet Onkologi och Patologi, MV. (creator_code:org_t)
Lunds universitet Individuell Bröstcancerbehandling. (creator_code:org_t)
Lunds universitet Onkologi och Patologi, Kampradlab. (creator_code:org_t)
Lunds universitet Bröst- och ovarialcancer. (creator_code:org_t)
visa färre...
2018
Engelska.
Ingår i: International Journal of Cancer. - John Wiley & Sons. - 0020-7136. ; 142:3, s. 618-628
Läs hela texten (fulltext)
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response-guided treatment adjustment. The role of early transcriptional changes in predicting response to neoadjuvant chemotherapy plus bevacizumab was investigated. One-hundred-and-fifty patients with large, operable and locally advanced HER2-negative breast cancer received epirubicin and docetaxel, with the addition of bevacizumab. Patients underwent tumor biopsies at baseline, after Cycle 2 and at the time of surgery. The primary end point, pCR, and its relation with the secondary endpoints event-free survival (EFS), overall survival (OS) and gene expression profiles, are reported. The pCR rate was 13% (95% CI 8.6-20.2), with significantly more pCRs among triple-negative [28% (95% CI 14.8-45.4)] than among hormone receptor positive (HR+) tumors [9% (95% CI 4.6-16.3); (OR=3.9 [CI=1.5-10.3])]. pCR rates were not associated with EFS or OS. PAM50 subtypes significantly changed after Cycle 2 (p=0.03) and an index of absolute changes in PAM50 correlations between these time-points was associated with EFS [HR=0.62 (CI=0.3-1.1)]. In univariable analyses, signatures for angiogenesis, proliferation, estrogen receptor signaling, invasion and metastasis, and immune response, measured after Cycle 2, were associated with pCR in HR+ tumors. Evaluation of changes in molecular subtypes and other signatures early in the course of neoadjuvant treatment may be predictive of pCR and EFS. These factors may help guide further treatment and should be considered when designing neoadjuvant trials.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

AIMS
Breast cancer
Neoadjuvant
PAM50
Pathological complete response
Phase 2 trial

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy